Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011
Rituximab Monotherapy for Patients With Recurrent Primary CNS Lymphoma
Neurol 76:929-930, Batchelor,T.T.,et al, 2011
Fulminant Encephalopathy With Basal Ganglia Hyperintensities in HIV-Infected Drug Users
Neurol 76:787-794, Newsome,S.D.,et al, 2011
Percutaneous Vascular Interventions for Acute Ischemic Stroke
Stroke 42:e31-e32, ORourke,K.,et al, 2011
Stem Cell Transplantation for Ischemic Stroke
Stroke 42:e33, Boncoraglio,G.B.,et al, 2011
Screening for Fitness to Drive After Stroke: A Systematic Review and Meta-Analysis
Neurol 76:747-756, e35, Devos,H.,et al, 2011
Increased Risk of Stroke After Discontinuation of Acetlysalicylic Acid: A UK Primary Care Study
Neurol 76:740-746, Rodr�guez,L.A.G.,et al, 2011
Increasing Incidence of Ischemic Stroke in Patients With HIV Infection
Neurol 76:444-450, Ovbiagele,B. &Nath,A., 2011
Child Development Following In Utero Exposure: Levetiracetam vs Sodium Valproate
Neurol 76:383-389, Shallcross,R.,et al, 2011
Hemicraniectomy in Malignant Middle Cerebral Artery Infarction
Stroke 42:513-516, Staykov,D. &Gupta,R., 2011
Incidence and Predictors of Myocardial Infarction After Transient Ischemic Attack: A Population-Based Study
Stroke 42:935-940, Burns,J.D.,et al, 2011
Hemorrhagic Transformation of Childhood Arterial Ischemic Stroke
Stroke 42:941-946, Beslow,L.A.,et al, 2011
Bridging Intravenous-Inta-Arterial Rescue Strategy Increases Recanalization and the Likelihood of a Good Outcome in Nonresponder Intravenous Tissue Plasminogen Activator-Treated Patients: A Case-Control Study
Stroke 42:993-997, 880, Rubiera,M.,et al, 2011
Subtherapeutic Warfarin Is Not Associated With Increased Hemorrhage Rates in Ischemic Strokes Treated With Tissue Plasminogen Activator
Stroke 42:1041-1045, Vergouwen,M.D.I.,et al, 2011
Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
NEJM 364:1134-1143, McCormack,M.,et al, 2011
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
NEJM 364:1126-1133, Chen,P.,et al, 2011
Mycophenolate Mofetil May Be Effective in CNS Sarcoidosis But Not in Sarcoid Myopathy
Neurol 76:1168-1172, Androdias,G.,et al, 2011
Lingual Hematoma After Thrombolytic Therapy
NEJM 364:e13, Vijayan,S. &Chase,A., 2011
Tumefactive Demyelination, an Uncommon Form of Tacrolimus Neurotoxicity
Neurol 76:672-674, Kim,S.H.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
Arch Neurol 68:186-191, Miravalle,A.,et al, 2011
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis
Ann Neurol 69:75-82, Comi,G.,et al, 2011
Differential Diagnosis of Bilateral Abnormalities of the Basal Ganglia and Thalamus
RadioGraphics 31:5-30, Hegde,A.N.,et al, 2011
CSF Complements Serum for Evaluating Paraneoplastic Antibodies and NMO-IgG
Neurol 76:1108-1110, McKeon,A.,et al, 2011
A Randomized Trial of Prenatal Versus Postnatal Repair of Myelomeningocele
NEJM 364:993-1004, 1076, Adzick,N.S.,et al, 2011
Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease
Neurol 76:1372-1376, Sone, J.,et al, 2011
Pediatric Neurological Complications of 2009 Pandemic Influenza A (H1N1)
Arch Neurol 68:455-462, Kedia, S.,et al, 2011
Efficacy and Safety of Mitoxantrone in Patients with Highly Relapsing Neuromyelitis Optica
Arch Neurol 68:473-479, Kim, S.H.,et al, 2011
Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children
Neurol 76:1338-1343, Arya, R.,et al, 2011
Prevalence of MRI-defined recent silent ischemia and associated bleeding risk with thrombolysis
Neurol 76:1288-1295, Tisserand, M.,et al, 2011
Diagnosis and management of transient ischaemic attack and ischaemic stroke in the acute phase
BMJ 342:d1938, McArthur, K.S.,et al, 2011
Clinicopathologic Conference, hemophagocytic lymphohistiocytosis
NEJM 364:1259-1270, Case 10-2011, 2011
VGKC antibodies in pediatric encephalitis presenting with status epilepticus
Neurology 76:1252-1255, Suleiman, J.,et al, 2011
Anticoagulation in Patients with Stroke With Infective Edocarditis Is Safe
Stroke 42:1795-1796,1799, Rasmussen, R.V., 2011
Anticoagulation Should Not Be Used in Most Patients With Stroke With Infective Endocarditis
Stroke 42:1797-1798,1799, Sila, C., 2011
Oral vs Intratympanic Corticosteroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss
JAMA 305(20):2071-2079,2114, Rauch, S.D.,et al, 2011
Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine
Neurol 76:1780-1781, Tong, D., 2011
Safety and Outcomes of Intravenous Thrombolysis in Stroke Mimics
Stroke 42:1771-1774, Tsivgoulis, G.,et al, 2011
Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation
Stroke 42:1717-1721, Jowett, S.,et al, 2011
Clinical and MRI characteristics of acute migrainous infarction
Neurol 76:1911-1917, Wolf, M.E.,et al, 2011
Cannabis Use, Ischemic Stroke, and Multifocal Intracranial Vasoconstriction
Stroke 42:1778-1780, Wolff, V.,et al, 2011
Comparison of IVIg and PLEX in patients with myasthenia gravis
Neurol 76:2017-2023, Barth, D.,et al, 2011
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke
NEJM 364:22, Wechsler, L.R., 2011
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
An unusual cause of stroke and hypoxia
BMJ 342:c7200, Bell, S.L. & Eveson, D.J., 2011
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Statin Use Following Intracerebral Hemorrhage
Arch Neurol 68:573-579, Westover, M.B.,et al, 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011